KR20230131222A - 가용형 clec2를 이용한 암 환자에 있어서의 혈전증리스크의 예측 방법 - Google Patents
가용형 clec2를 이용한 암 환자에 있어서의 혈전증리스크의 예측 방법 Download PDFInfo
- Publication number
- KR20230131222A KR20230131222A KR1020237025829A KR20237025829A KR20230131222A KR 20230131222 A KR20230131222 A KR 20230131222A KR 1020237025829 A KR1020237025829 A KR 1020237025829A KR 20237025829 A KR20237025829 A KR 20237025829A KR 20230131222 A KR20230131222 A KR 20230131222A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- concentration
- soluble
- clec2
- thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G01N33/57484—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/7056—Selectin superfamily, e.g. LAM-1, GlyCAM, ELAM-1, PADGEM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JPJP-P-2021-003671 | 2021-01-13 | ||
| JP2021003671 | 2021-01-13 | ||
| PCT/JP2022/000891 WO2022154045A1 (ja) | 2021-01-13 | 2022-01-13 | 可溶型ｃｌｅｃ２を用いた癌患者における血栓症リスクの予測方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230131222A true KR20230131222A (ko) | 2023-09-12 |
Family
ID=82448474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237025829A Pending KR20230131222A (ko) | 2021-01-13 | 2022-01-13 | 가용형 clec2를 이용한 암 환자에 있어서의 혈전증리스크의 예측 방법 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240288435A1 (https=) |
| EP (1) | EP4279606A4 (https=) |
| JP (1) | JP7808059B2 (https=) |
| KR (1) | KR20230131222A (https=) |
| CN (1) | CN116761895A (https=) |
| WO (1) | WO2022154045A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090297508A1 (en) * | 2005-04-25 | 2009-12-03 | University Of Yamanashi | Compositions and methods for treating hemostasis disorders associated with clec-2 signal transduction |
| CA2610910A1 (en) | 2005-06-09 | 2006-12-21 | Paul H. Mcpherson | Methods and compositions for the diagnosis of venous thromboembolic disease |
| CN104093741B (zh) * | 2011-03-22 | 2016-12-07 | 公益财团法人癌研究会 | 小鼠抗Aggrus单克隆抗体 |
| JP6078845B2 (ja) * | 2012-09-28 | 2017-02-15 | 株式会社Ｌｓｉメディエンス | 可溶型ｃｌｅｃ−２に基づく血小板活性化測定方法 |
| CA2993624A1 (en) * | 2015-08-07 | 2017-02-16 | Thomas Helledays Stiftelse For Medicinsk Forskning | Method for diagnosisng cancer or cancer-associated thrombosis by measuring levels of h3cit in plasma |
| FR3048001B1 (fr) | 2016-02-18 | 2018-02-09 | Diagnostica Stago | Methode de dosage des d-dimeres specifiques de la maladie thromboembolique veineuse |
| EP4113524A4 (en) * | 2020-02-28 | 2024-03-06 | LSI Medience Corporation | METHOD FOR MEASURING PLATELE ACTIVATION BASED ON SOLUBLE CLEC-2 AND PLATELE COUNT |
-
2022
- 2022-01-13 EP EP22739450.9A patent/EP4279606A4/en active Pending
- 2022-01-13 CN CN202280009906.2A patent/CN116761895A/zh active Pending
- 2022-01-13 JP JP2022575626A patent/JP7808059B2/ja active Active
- 2022-01-13 US US18/261,155 patent/US20240288435A1/en active Pending
- 2022-01-13 KR KR1020237025829A patent/KR20230131222A/ko active Pending
- 2022-01-13 WO PCT/JP2022/000891 patent/WO2022154045A1/ja not_active Ceased
Non-Patent Citations (5)
| Title |
|---|
| [비특허문헌 1] Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l＇Hotel Dieu de Paris, Vol 3. Paris: Bailliere. 1865; 654-712 in French |
| [비특허문헌 2] Freesia Horsted et al., PLoS Med. 2012 Jul; 9(7): e1001275 |
| [비특허문헌 3] Lyman GH et al. J Clin Oncol 31(17):2189-2204, 2013 |
| [비특허문헌 4] Kunita A et al. Am J Pathol. 170:1337-1347 (2007) |
| [비특허문헌 5] 이노우에 가츠에 외, 혈전 지혈지 22(6):348-362(2011) |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116761895A (zh) | 2023-09-15 |
| US20240288435A1 (en) | 2024-08-29 |
| EP4279606A1 (en) | 2023-11-22 |
| EP4279606A4 (en) | 2024-12-18 |
| WO2022154045A1 (ja) | 2022-07-21 |
| JP7808059B2 (ja) | 2026-01-28 |
| JPWO2022154045A1 (https=) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Blann et al. | Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes | |
| Tian et al. | The diagnostic value of serum C-reactive protein, procalcitonin, interleukin-6 and lactate dehydrogenase in patients with severe acute pancreatitis | |
| Shorr et al. | D-dimer assay predicts mortality in critically ill patients without disseminated intravascular coagulation or venous thromboembolic disease | |
| Favaloro | Laboratory testing in disseminated intravascular coagulation | |
| US9435814B2 (en) | Methods and kits for diagnosing obstructive sleep apnea | |
| Ide et al. | Prediction of postoperative complications in elderly patients with hepatocellular carcinoma | |
| US12590978B2 (en) | Method for measuring platelet activation based on soluble CLEC-2 and platelet count | |
| Xue et al. | Diagnosis of sepsis with inflammatory biomarkers, cytokines, endothelial functional markers from SIRS patients | |
| Celebi et al. | The association between thrombotic and inflammatory biomarkers and lower‐extremity peripheral artery disease | |
| Qin et al. | Association between higher systemic immune inflammation index (SII) and deep vein thrombosis (DVT) in patients with aneurysmal subarachnoid hemorrhage (aSAH) after endovascular treatment | |
| Zhang et al. | The early predictive role of complement C3 and C4 in patients with acute pancreatitis | |
| Albini et al. | D-dimer levels remain elevated in acute aortic dissection after 24 h | |
| JP2004503254A (ja) | リポタンパク質と急性期タンパク質との複合体を検出し、系の不全または致死のリスクの増加を予測する方法 | |
| KR20230131222A (ko) | 가용형 clec2를 이용한 암 환자에 있어서의 혈전증리스크의 예측 방법 | |
| Yin et al. | Prognostic value of the International Society on Thrombosis and Haemostasis scoring system for overt disseminated intravascular coagulation in emergency department sepsis | |
| El-Akabawy et al. | Prognostic value of vascular endothelial growth factor in sepsis syndrome | |
| EP4350350A1 (en) | Method for assessing risk of hemorrhagic stroke using soluble clec2 | |
| KR20240017000A (ko) | 가용형 clec2를 이용한 급성 뇌혈관 장애의 리스크 평가방법 | |
| Hunt et al. | Venous thromboembolism and thrombophilia testing | |
| HK40085757A (en) | Method for measuring platelet activation based on soluble clec-2 and platelet count | |
| Wang et al. | Predictive value of combined CRP/ALB ratio and DD/FIB ratio for MODS in patients with severe polytrauma. | |
| Celik | The value of blood parameters as a diagnostic inflammatory biomarker for inverted papilloma | |
| Mahmoud et al. | Reliability of plasma von Willebrand factor antigen in prediction of esophageal varices in patients with liver cirrhosis | |
| Lippi et al. | Laboratory diagnostics in septic disseminated intravascular coagulation | |
| Shan et al. | Evaluation of Prognosis and Risk of Death by NLR, Plasma DD and CRP/ALB Ratio in Patients with PTE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |